September 29, 2008 - Rhode Island Hospital is the first site to treat endometrial cancer using Xoft’s Axxent Electronic Brachytherapy System.
The system, first approved for early stage breast cancer, is now FDA approved for treatment of uterine cancer. The first patient received treatment on Sept. 9 at the Providence, RI hospital.
The Axxent Electronic Brachytherapy System by Xoft uses a miniaturized X-ray source to deliver localized and targeted radiation treatment to reduce the risk of recurrence of the disease. It is inserted into the tumor through a catheter to the tumor site and allows medical staff administering the treatment to be in the room with the patient. The new treatment requires fewer sessions than traditional radiation and eliminates the use of radioactive isotopes, resulting in better outcomes for patients, less exposure to radiation and fewer side effects. The system was designed to improve survival and reduce recurrence of cancer.
Rhode Island Hospital, the first in the world to use the Axxent System for the treatment of endometrial cancer, was also among the first in the country to use the system in the treatment of early stage breast cancer, and has seen positive results since it was FDA approved in 2007.